72 results about "Immune gene" patented technology

A process for preparing the antigen protein used for hog cholera vaccine includes extracting hog cholera virus RNA, reverse transcription to obtain the immune gene E2 of hog cholera virus, using E2 as template for PCR while inserting them to expression carrier of Bichia yeast, introducing the recombinant expression carrier to Bichia yeast, screening the recombinant Bichia yeast, discriminating its expression product testing its immunoactivity, determining the chosen recombinant yeast, testing and analyzing its culture condition, choosing the optimal culture condition, culturing the recombinant yeast and preparing the antigen protein of said vaccine.

Disclosed is a complex immuno-gene medical composition for activating NK cells to enhance a host immune system. The composition includes a plurality of cytokines, including Th1 and Th2 cytokines. Th2 cytokines antagonize TGF-β inhibiting NK cells to disable the inhibition of the immune system. Th1 cytokines activate NK cells in a host to enhance the host's ability to fight against tumor cells. By use of the complex immuno-gene medical composition, removal of tumor cells is expected.

The invention discloses an application of a scoring system based on an immunogene pair in prediction of immunotherapy curative effect and prognosis of a non-small cell lung cancer patient. The scoring system disclosed by the invention is carried out based on the following four immune related gene pairs: CCL2 and VEGFA genes, CDK1 and CXCL9 genes, HLA-DOB and LCK genes, and IL-12A and TBX21 genes. The IRGP index (IRGPI) calculated based on an immune gene pair scoring system constructed by the invention is significantly related to the progression-free lifetime of a non-small cell lung cancer patient receiving anti-PD-1 immunotherapy. Therefore, the four immune-related gene pairs and the scoring system constructed according to the four immune-related gene pairs can be used for performing curative effect and prognosis prediction on the non-small cell lung cancer patient receiving anti-PD-1 immunotherapy.

The invention provides an O-type foot and mouth disease virus strain with improved replication titer as well as a construction method and application thereof, and belongs to the technical field of biological products. Through a reverse genetic manipulation technology of the foot and mouth disease virus, a G-H ring gene of the foot and mouth disease virus O / NXYCh / CHA / 2018 strain is further used for replacing a corresponding gene on a recombinant virus skeleton of a main immune gene of the chimeric foot and mouth disease virus O / XJ / CHA / 2017 strain, the time of causing 100% infected cell lesion by the constructed recombinant virus rHN / XJ / NXGH is remarkably shortened to 12 h, and the time of causing 100% infected cell lesion by the recombinant virus rHN / XJ / NXGH is remarkably shortened to 12 h. And the replication titer of infected cells for 12 hours is improved by more than 5 times. The recombinant virus is continuous in passage and good in hereditary stability, and replacement of the G-H ring does not affect immunogenicity of the vaccine. Therefore, the recombinant foot-and-mouth disease virus strain rHN / XJ / NXGH provided by the invention has the potential to be used as a vaccine candidate strain for effectively preventing and controlling the O-type foot-and-mouth disease in China.

The invention discloses a microRNA (micro ribonucleic acid) related to soybean phytophthora resistance and belongs to the field of molecular biology of soybeans. 223 phytophthora-resistant genes and 256 miRNAs are obtained by means of screening known relevant disease-resistant immune genes. A phytophthora-resistance-related miRNA-Target predicting system is established by means of expression profile sequencing, rigorous bioinformatics analysis and real-time quantitative PCR (polymerase chain reaction) detection and can predict functions of the miRNAs, so that screening and identifying efficiency for soybean phytophthora resisting genes and the miRNAs is improved greatly. A MIRNA-target relation classification method is provided, that a Plant-pathogen interaction path plays a key role in phytophthora resisting is discovered, and that a gma-miR482c-3p serves as a main ingredient of the Plant-pathogen interaction path and is closely related to the soybean phytophthora resistance is verified.

The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy. As described herein, we have identified a unique signature termed AZA Immune gene set or AIM that differentiates patients with a low immune and high immune signature and is regulated by epigenetic drugs such as demethylating drugs, histone deacetylase inhibitors. In certain embodiments, patients with a high immune signature may benefit from immunotherapies such as anti PD1 or anti PDL1 antibodies or vaccines. In other embodiments, patients with a low immune signature or low AIM would be patients who would then benefit from treatment with epigenetic drugs and then subsequent immunotherapy.

Disclosed is a complex immuno-gene medical composition activating NK cells to enhance host immune system. The composition is usage of a combination of a plurality of cytokines, combined usage of the kinds of Th1 and Th2 cytokines. Th2 cytokine antagonizes TGF-β inhibiting NK cells to disable the inhibition of immune system, and Th1 cytokine activates NK cells in host to enhance the ability fighting against tumor cells. By means of the complex immuno-gene medical composition, removal of tumor cells is expectable.

The invention concerns a tbid gene, protein coding by tbid gene and uses of said gene and protein in tumor drug preparation. In the invention, single chain antibody e23sFv gene which can idiocraticly identify and bind HER-2 positive tumor cell is used to construct a tbid gene with PEA transmembrane structural domain and active truncated bid gene (tbid)which has strong specificity,high activity ,low immunogenicity,sustainable execution on tumor. The invention constructs secretion type immunological target gene. after gene is expressed and secreted, its can produce effector molecule to kill tumor cell. The gene therapy strategy possessing simultaneously the cell immunity and humoral immunity character has obvious advantages compared with other strategy. Immunological tbid gene the invention constructed is safe, highly effective and continuous effect. The invention is hoped to provide a novel method for HER-2 tumor target therapy.